Seikagaku has a unique business model of supplying products through external partnerships in Japan and overseas in collaboration with pharmaceuticals and medical device sales companies. In this way, it intends to focus and develop its business activities without having an in-house pharmaceuticals sales division.

The Pharmaceuticals business is Seikagaku’s core business segment.

As a pioneer and leading company in glycoscience, Seikagaku provides high-quality products globally with its unique technologies and knowledge that has been developed for many decades. 
 

Seikagaku manufactures pharmaceuticals and medical devices with, as their main ingredient, glycosaminoglycans (GAG) such as hyaluronic acid, which are the structural components of glycoconjugates, and also products based on enzymes that act on GAG. To deliver these products to patients globally, Seikagaku forms partnerships with pharmaceutical companies that have expertise in each market, including Japan.

Through their activities, our partners, in conformance with laws and regulations on pharmaceutical sales, provide appropriate information on product efficacy, safety, quality, and other matters to physicians on a timely basis. Seikagaku, in close cooperation with sales partners, formulates sales strategies, supports preparation of product information materials, analyzes the market environment, including information on competing products, and collaborates with academic societies. Through these activities, we support sales partner activities and appropriately promote market penetration for our products.

As part of product life cycle management, Seikagaku is implementing product modifications that respond to needs of a changing market. One example is the conversion of the material for syringes, used for the joint function improving agent ARTZ, from glass to plastic. Through these efforts, we are adding value to our products.

Furthermore, we have been accelerating overseas business expansion in recent years. We are working to increase sales in countries where we already do business, and to meet global medical needs, we are implementing a plan to introduce existing products and products in development into new markets.